SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer ; volume:189 ; number:2 ; day:19 ; month:7 ; year:2021 ; pages:317-331 ; date:9.2021
Breast cancer research and treatment ; 189, Heft 2 (19.7.2021), 317-331, 9.2021
- Creator
-
Alfarsi, Lutfi H.
El Ansari, Rokaya
Craze, Madeleine L.
Mohammed, Omar J.
Masisi, Brendah K.
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-021-06298-1
- URN
-
urn:nbn:de:101:1-2021103122464464671782
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Alfarsi, Lutfi H.
- El Ansari, Rokaya
- Craze, Madeleine L.
- Mohammed, Omar J.
- Masisi, Brendah K.
- Ellis, Ian O.
- Rakha, Emad A.
- Green, Andrew R.
- SpringerLink (Online service)
Other Objects (12)
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases
Mec1p associates with functionally compromised telomeres
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases
Mec1p associates with functionally compromised telomeres
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases